Poly Medicure
NSE
₹ 0.00
0.00 (0.00)%
Small-cap
With a market cap of ₹18.90L Cr.
EX-Date | Purpose |
---|---|
24 05 2021 | Dividend & Audited Results Iinter alia to consider the following: a) To consider and approve the Audited Financial Results (Consolidated & Standalone) of the Company for the financial year ended on 31st March, 2021. b) To consider recommendation of Final Dividend, if any, on the Equity Shares for the financial year ended on 31st March, 2021. c) To transact any other matter which the Board may deem fit. |
29 07 2021 | Quarterly Results |
01 11 2021 | Quarterly Results |
31 01 2022 | Quarterly Results |
24 05 2022 | Final Dividend & Audited Results |
04 08 2022 | Quarterly Results |
04 11 2022 | Quarterly Results |
28 01 2023 | Quarterly Results |
09 05 2023 | Final Dividend & Audited Results |
07 08 2023 | Quarterly Results |
04 11 2023 | Quarterly Results |
31 01 2024 | Quarterly Results |
08 03 2024 | Inter alia, to consider the following:- a) Business Plan for Financial Year 2024-25. b) consider and evaluate a proposal for raising of funds, in one or more tranches, through permissible mode(s) and / or combination(s) thereof as may be considered appropriate, by way of raising of debts, issuance of any instruments or securities, through private placement, preferential issue, rights issue, qualified institutions placement or such other methods or combinations thereof as may be decided by the Board, subject to such approvals as may be required, and to transact other businesses with the permission of the Chairperson. |
28 10 2024 | Employees Stock Option Plan & Quarterly Results |
03 02 2025 | Quarterly Results |
06 05 2025 | Final Dividend & Audited Results |
No News data available